

**Chemotherapeutics**

#	Patent #	Title	Inventor(s)	Features
1	6042826	Method for Inducing Apoptosis of Primary Central Nervous System B cell Lymphomas	Caligiuri et al.	Treatment of central nervous system (CNS) lymphomas with Fas-mediated cytotoxic antibodies and/or in combination with other chemotherapeutics to induce apoptosis.
2	5286726	Difluoroglumatic Acid Conjugates with Folates and Anti-Folates for the Treatment of Neoplastic Diseases	McGuire et al.	Difluoroglumatic acid conjugates with folates and anti-folates useful for treating cancers; e.g. neoplastic diseases including leukemia, melanomas, carcinomas, sarcomas and mixed neoplasias.
3	4918056	2-substituted Arabinopyranosyl Nucleosides and Nucleotides	Bobek et al.	Novel arabinopyranosyl nucleosides and nucleotides with particular structure and few toxic side-effects. Exhibit useful antitumor, antiviral and antimicrobial activities.
4	6977271	Method for Inhibition of Angiogenesis and Vasculogenesis	Ip et al.	Oral administration of conjugated linoleic acid (CLA) isomers inhibit angiogenesis in a solid tumor. Economically favorable for long-term treatment.
5	6939893	Method of Reducing Toxicity of Anticancer Agents	Rustum, Cao & Durrani	Reduction of toxicity of anticancer agents, specifically irinotecan and taxol, via administration of particular selenium compounds. Data is presented for in vivo studies in two animal models.
6	6620779	Method of Enhancing the Efficacy of Anti-Tumor Agents	Piver et al.	Use of erythropoietin (EPO) to increase the efficacy of chemotherapeutic agents for treating solid tumors by improving the hematocrit.
7	6426094	Method of Enhancing the Efficacy of Anti-Tumor Agents	Piver et al.	Use of erythropoietin (EPO) to increase the efficacy of chemotherapeutic agents for treating solid tumors by improving the hematocrit. Differentiated from '779 and '620 by Claim 5 which specifies that the EPO-like substance has increased glycosylation sites compared to EPO.
8	6171620	Method of Enhancing the Efficacy of Anti-Tumor Agents	Piver et al.	Use of erythropoietin (EPO) to increase the efficacy of chemotherapeutic agents for treating solid tumors by improving the hematocrit.
9	5972907	Synthetic Core 2-like Branched Structures Containing GalNAc-lewis. sup.x and Neu5Ac.alpha.2-3Gal.beta.1-3GalNAc Sequences as Novel Ligands for Selectin	Matta et al.	Galnac-lewis compounds which bind to selectin receptors and may modulate autoimmune, inflammation, cancer, and related processes by intervening with cell-cell adhesion events.
10	5811452	Taxoid Reversal Agents for Drug-Resistance in Cancer Chemotherapy and Pharmaceutical Compositions Thereof	Ojima et al.	Taxoids that prevent multidrug resistance associated with the use of anthracyclines, Taxol, Taxotere, vinblastine and vincristine.
11	7097836	Method for increasing the efficacy of anti-tumor agents by anti-endoglin antibody	Seon; Ben K.	Combination approach for cancer therapy and other angiogenesis-associated diseases such as rheumatoid arthritis. Enhances chemotherapy by employing anti-endoglin MAbs or antigen binding fragments. Endoglin is also known as ENG gene.
12	5393737	Cytotoxic Drug Conjugates for Treatment of Neoplastic Diseases	Mayers et al.	Non-toxic cytotoxic drug minimizes effect on normal cells. Ligand-carbohydrate-cytotoxic drug conjugates, aka toxogens, for treating cancer, autoimmunities, or allergies or any condition that requires elimination of specific cell populations that express an addressible receptor. Preferred ligands include cytokines and growth factors such as transferrin, epidermal growth factor, granulocyte macrophage - colony stimulating factor (GM-CSF).